000164455 001__ 164455
000164455 005__ 20240320105650.0
000164455 0247_ $$2doi$$a10.3233/JAD-200520
000164455 0247_ $$2pmid$$apmid:33104026
000164455 0247_ $$2ISSN$$a1387-2877
000164455 0247_ $$2ISSN$$a1875-8908
000164455 037__ $$aDZNE-2022-01007
000164455 041__ $$aEnglish
000164455 082__ $$a610
000164455 1001_ $$aHallab, Asma$$b0
000164455 245__ $$aImpairment of Everyday Spatial Navigation Abilities in Mild Cognitive Impairment Is Weakly Associated with Reduced Grey Matter Volume in the Medial Part of the Entorhinal Cortex.
000164455 260__ $$aAmsterdam$$bIOS Press$$c2020
000164455 3367_ $$2DRIVER$$aarticle
000164455 3367_ $$2DataCite$$aOutput Types/Journal article
000164455 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710928560_2064
000164455 3367_ $$2BibTeX$$aARTICLE
000164455 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164455 3367_ $$00$$2EndNote$$aJournal Article
000164455 520__ $$aResearch in rodents identified specific neuron populations encoding information for spatial navigation with particularly high density in the medial part of the entorhinal cortex (ERC), which may be homologous with Brodmann area 34 (BA34) in the human brain.The aim of this study was to test whether impaired spatial navigation frequently occurring in mild cognitive impairment (MCI) is specifically associated with neurodegeneration in BA34.The study included baseline data of MCI patients enrolled in the Alzheimer's Disease Neuroimaging Initiative with high-resolution structural MRI, brain FDG PET, and complete visuospatial ability scores of the Everyday Cognition test (VS-ECog) within 30 days of PET. A standard mask of BA34 predefined in MNI space was mapped to individual native space to determine grey matter volume and metabolic activity in BA34 on MRI and on (partial volume corrected) FDG PET, respectively. The association of the VS-ECog sum score with grey matter volume and metabolic activity in BA34, APOE4 carrier status, age, education, and global cognition (ADAS-cog-13 score) was tested by linear regression. BA28, which constitutes the lateral part of the ERC, was used as control region.The eligibility criteria led to inclusion of 379 MCI subjects. The VS-ECog sum score was negatively correlated with grey matter volume in BA34 (β= -0.229, p = 0.022) and age (β= -0.124, p = 0.036), and was positively correlated with ADAS-cog-13 (β= 0.175, p = 0.003). None of the other predictor variables contributed significantly.Impairment of spatial navigation in MCI is weakly associated with BA34 atrophy.
000164455 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000164455 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164455 650_7 $$2Other$$a18F-fluorodeoxyglucose
000164455 650_7 $$2Other$$aEntorhinal cortex
000164455 650_7 $$2Other$$agrid cells
000164455 650_7 $$2Other$$amagnetic resonance imaging
000164455 650_7 $$2Other$$amild cognitive impairment
000164455 650_7 $$2Other$$apositron emission tomography
000164455 650_7 $$2Other$$aspatial navigation
000164455 650_7 $$2Other$$avolumetry
000164455 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000164455 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000164455 650_2 $$2MeSH$$aActivities of Daily Living
000164455 650_2 $$2MeSH$$aAged
000164455 650_2 $$2MeSH$$aAged, 80 and over
000164455 650_2 $$2MeSH$$aAtrophy
000164455 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000164455 650_2 $$2MeSH$$aCognitive Dysfunction: pathology
000164455 650_2 $$2MeSH$$aCognitive Dysfunction: physiopathology
000164455 650_2 $$2MeSH$$aEntorhinal Cortex: diagnostic imaging
000164455 650_2 $$2MeSH$$aEntorhinal Cortex: pathology
000164455 650_2 $$2MeSH$$aFemale
000164455 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000164455 650_2 $$2MeSH$$aGray Matter: diagnostic imaging
000164455 650_2 $$2MeSH$$aGray Matter: pathology
000164455 650_2 $$2MeSH$$aHumans
000164455 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000164455 650_2 $$2MeSH$$aMale
000164455 650_2 $$2MeSH$$aMiddle Aged
000164455 650_2 $$2MeSH$$aOrgan Size
000164455 650_2 $$2MeSH$$aPositron-Emission Tomography
000164455 650_2 $$2MeSH$$aRadiopharmaceuticals
000164455 650_2 $$2MeSH$$aSpatial Navigation: physiology
000164455 7001_ $$0P:(DE-2719)9000635$$aLange, Catharina$$b1$$udzne
000164455 7001_ $$aApostolova, Ivayla$$b2
000164455 7001_ $$aÖzden, Cansu$$b3
000164455 7001_ $$0P:(DE-2719)2811969$$aGonzalez Escamilla, Gabriel$$b4$$udzne
000164455 7001_ $$aKlutmann, Susanne$$b5
000164455 7001_ $$aBrenner, Winfried$$b6
000164455 7001_ $$0P:(DE-2719)2810708$$aGrothe, Michel J$$b7$$udzne
000164455 7001_ $$aBuchert, Ralph$$b8
000164455 7001_ $$aInitiative, Alzheimer’s Disease Neuroimaging$$b9$$eCollaboration Author
000164455 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-200520$$gVol. 78, no. 3, p. 1149 - 1159$$n3$$p1149 - 1159$$tJournal of Alzheimer's disease$$v78$$x1387-2877$$y2020
000164455 8564_ $$uhttps://pub.dzne.de/record/164455/files/DZNE-2022-01007_Restricted.pdf
000164455 8564_ $$uhttps://pub.dzne.de/record/164455/files/DZNE-2022-01007_Restricted.pdf?subformat=pdfa$$xpdfa
000164455 909CO $$ooai:pub.dzne.de:164455$$pVDB
000164455 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000635$$aExternal Institute$$b1$$kExtern
000164455 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811969$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000164455 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810708$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000164455 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000164455 9141_ $$y2020
000164455 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000164455 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000164455 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000164455 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2021$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-18
000164455 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-18
000164455 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000164455 980__ $$ajournal
000164455 980__ $$aVDB
000164455 980__ $$aI:(DE-2719)1510100
000164455 980__ $$aUNRESTRICTED